According to Takeda Pharmaceutical's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.65408. At the end of 2023 the company had a P/S ratio of 1.67.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.67 | 2.01% |
2022 | 1.64 | 18.76% |
2021 | 1.38 | -26.85% |
2020 | 1.89 | -9.59% |
2019 | 2.09 | 28.42% |
2018 | 1.62 | -41.66% |
2017 | 2.78 | 36.85% |
2016 | 2.04 | -22.01% |
2015 | 2.61 | 27.24% |
2014 | 2.05 | -5.8% |
2013 | 2.18 | 18.43% |
2012 | 1.84 | -2.25% |
2011 | 1.88 | -19.67% |
2010 | 2.34 | 12.02% |
2009 | 2.09 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 4.12 | 149.20% | ๐บ๐ธ USA |
![]() Novartis NVS | 3.98 | 140.57% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 2.37 | 43.16% | ๐บ๐ธ USA |
![]() Amgen AMGN | 5.39 | 225.67% | ๐บ๐ธ USA |
![]() Sanofi SNY | 2.84 | 71.94% | ๐ซ๐ท France |
![]() Merck MRK | 4.63 | 179.77% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 2.19 | 32.50% | ๐ฌ๐ง UK |
![]() Seagen
SGEN | 18.6 | 1,021.63% | ๐บ๐ธ USA |
![]() Dr. Reddy's RDY | 3.48 | 110.42% | ๐ฎ๐ณ India |